Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: Results from an integrated analysis

Hematological Oncology

Volumn 29, Issue 4, 2011, Pages 177-184

  Pettengell, R ^a   Schwenkglenks, M ^b   Bacon, P ^c   Lawrinson, S ^d   Duehrsen, U ^e  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BASEL   (Switzerland)

^c AMGEN INC   (United States)

^d AMGEN LTD   (United Kingdom)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Febrile neutropenia; Non Hodgkin lymphoma; Pegfilgrastim; Relative dose intensity

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL (TOPIC); DRUG DOSE REDUCTION; DRUG EFFICACY; FEBRILE NEUTROPENIA; HUMAN; INCIDENCE; MEDLINE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; RECOMBINANT PROTEINS;

EID: 83555177626     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.982     Document Type: Article

References (35)

1. Aapro MS, Cameron DA, Pettengell R, et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453.
2. Balducci L, Al-Halawani H, Charu V, et al. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim. Oncologist 2007; 12: 1416-1424.
3. Pettengell R, Schwenkglenks M, Leonard R, et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2008; 16: 1299-1309.
4. Repetto L, Biganzoli L, Koehne CH, et al. EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer. Eur J Cancer 2003; 39: 2264-2272.
5. Leonard RC, Miles D, Thomas R, Nussey F. Impact of neutropenia on delivering planned adjuvant chemotherapy: UK audit of primary breast cancer patients. Br J Cancer 2003; 89: 2062-2068.
6. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004; 22: 4302-4311.
7. Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008; 87: 429-430.
8. Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44: 2069-2076.
9. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
10. Crawford J. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 2003; 30 (4 Suppl. 13): 24-30.
11. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
12. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727-731.
13. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006; update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205.
14. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Myeloid Growth Factors. V.1.2010. Last accessed 26 February 2010.
15. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003; 21: 514-519.
16. George S, Yunus F, Case D, et al. Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1691-1696.
17. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma 2003; 44: 1503-1508.
18. Moore T, Patel T, Segal M, et al. A single pegfilgrastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with non-Hodgkins lymphoma. American Society of Hematology Annual Meeting, 2003. Blood 2003; 102(11): Abstract 2365.
19. Burris HA, Belani CP, Kaufman PA, et al. Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small cell lung cancer, ovarian cancer, and non-Hodgkin's lymphoma: results of four multicenter, double-blind, randomized phase II studies. J Oncol Pract 2010; 6: 133-140.
20. Ozer H, Mirtsching B, Rader M, et al. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use. Oncologist 2007; 12: 484-494.
21. Lopez A, de Sevilla AF, Castaigne S, et al. Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomised phase II study. Blood 2004; 104: Abstract 3311.
22. Brusamolino E, Rusconi C, Montalbetti L, et al. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica 2006; 91: 496-502.
23. Mey UJM, Maier A, Schmidt-Wolf IGH, et al. Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Supoprt Care Cancer 2007; 15: 877-884.
24. Hartmann F, Zeynalova S, Nickenig C, et al. Peg-filgrastim (Peg-F) on day 4 of (R)CHOP-14 chemotherapy compared to day 2 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of a randomized trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). J Clin Oncol 2007; 25 (Suppl. 18S): 19511.
25. Woods MA, Lopez T, Thomas SP, Harwood H, Kettler SM. Incidence of febrile neutropenia in lymphoma patients receiving CHOP with day 1 or 2 pegfilgrastim. J Clin Oncol 2010; 28 (Suppl.): 18562.
26. Wolff M, Bentley M, Marlton P, et al. Pegfilgrastim to support CGOP-14 in elderly patients with non-Hodgkin's lymphoma. Leuk Lymph 2006; 47: 2344-2350.
27. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B cell lymphoma. N Engl J Med 2002; 346: 235-242.
28. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634-641.
29. Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 2003; 98: 2402-2409.
30. Picozzi VJ, Pohlman BL, Morrison VA, et al. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma. Oncology (Williston Park) 2001; 15: 1296-1306; discussion 1310-1291, 1314.
31. Bosly A, Bron D, Van Hoof A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008; 87: 277-283.
32. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-116.
33. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626-633.
34. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992; 80: 1430-1436.
35. Von Minckwitz G, Schwenkglenks M, Skacel T, et al. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropenia management: results from an integrated analysis. Eur J Cancer 2009; 45: 608-617.